Another study has shown that the cAMP/PKA pathway can promote the release of VEGF (Garg et al., 2017) and, in prostate cancer endothelial cells, the Gs-coupled β2 adrenergic receptor has been shown to induce an angiogenic switch, which occurs through the alteration of endothelial cell metabolism by inhibiting endothelial oxidative phosphorylation (Zahalka et al., 2017). Here, VEGFA is linked to prostate cancer.